About UsDainippon Sumitomo Pharma Co. Ltd (DSP) is a multi-billion dollar, top-ten listed pharmaceutical company in Japan with a diverse portfolio of pharmaceutical, animal health and food, and specialty products. DSP aims to produce innovative pharmaceutical products in the CNS field, designated as a frontier therapeutic area. DSP is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, DSP has more than 7,000 employees worldwide. Additional information about DSP is available through its corporate website at: www.ds-pharma.com Dainippon Sumitomo Pharma Europe Ltd (DSPE) was established in 1997 in London, UK. Dainippon Sumitomo Pharma America Inc (DSPA) was established in 1999 in Fort Lee, USA. In October 2009 DSP announced completion of the acquisition of Sepracor Inc, a US based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving large and growing markets and unmet medical needs. A merger between Sepracor and DSPA took place in April 2010, leading to a consolidation of DSP's two North American businesses. The combined company operated under the 'Sepracor' name. Sunovion Pharmaceueticals Inc. is the new company born (October 2010) from this union. Both Sunovion and DSPE are subsidiaries of DSP. At DSPE, the corporate values are translated into the following operational values:
Learn more about our Corporate Philosophy and Leadership. 
|
